Literature DB >> 22378924

Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase.

Mayra García1, Arik Cooper, Wei Shi, William Bornmann, Ricardo Carrion, Daniel Kalman, Gary J Nabel.   

Abstract

Ebola virus causes a fulminant infection in humans resulting in diffuse bleeding, vascular instability, hypotensive shock, and often death. Because of its high mortality and ease of transmission from human to human, Ebola virus remains a biological threat for which effective preventive and therapeutic interventions are needed. An understanding of the mechanisms of Ebola virus pathogenesis is critical for developing antiviral therapeutics. Here, we report that productive replication of Ebola virus is modulated by the c-Abl1 tyrosine kinase. Release of Ebola virus-like particles (VLPs) in a cell culture cotransfection system was inhibited by c-Abl1-specific small interfering RNA (siRNA) or by Abl-specific kinase inhibitors and required tyrosine phosphorylation of the Ebola matrix protein VP40. Expression of c-Abl1 stimulated an increase in phosphorylation of tyrosine 13 (Y(13)) of VP40, and mutation of Y(13) to alanine decreased the release of Ebola VLPs. Productive replication of the highly pathogenic Ebola virus Zaire strain was inhibited by c-Abl1-specific siRNAs or by the Abl-family inhibitor nilotinib by up to four orders of magnitude. These data indicate that c-Abl1 regulates budding or release of filoviruses through a mechanism involving phosphorylation of VP40. This step of the virus life cycle therefore may represent a target for antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378924      PMCID: PMC4794994          DOI: 10.1126/scitranslmed.3003500

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  57 in total

1.  Reprogramming control of an allosteric signaling switch through modular recombination.

Authors:  John E Dueber; Brian J Yeh; Kayam Chak; Wendell A Lim
Journal:  Science       Date:  2003-09-26       Impact factor: 47.728

Review 2.  Filovirus assembly and budding.

Authors:  Bettina Hartlieb; Winfried Weissenhorn
Journal:  Virology       Date:  2006-01-05       Impact factor: 3.616

3.  The nucleoprotein of Marburg virus is phosphorylated.

Authors:  S Becker; S Huppertz; H D Klenk; H Feldmann
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

Review 4.  Cardiotoxicity associated with targeting kinase pathways in cancer.

Authors:  Howard R Mellor; Alex R Bell; Jean-Pierre Valentin; Ruth R A Roberts
Journal:  Toxicol Sci       Date:  2010-12-22       Impact factor: 4.849

5.  pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN.

Authors:  Zhi-Yong Yang; Yue Huang; Lakshmanan Ganesh; Kwanyee Leung; Wing-Pui Kong; Owen Schwartz; Kanta Subbarao; Gary J Nabel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Context-dependent effects of L domains and ubiquitination on viral budding.

Authors:  Juan Martin-Serrano; David Perez-Caballero; Paul D Bieniasz
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Nedd4 regulates egress of Ebola virus-like particles from host cells.

Authors:  Jiro Yasuda; Mitsuyoshi Nakao; Yoshihiro Kawaoka; Hisatoshi Shida
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Abl tyrosine kinases are required for infection by Shigella flexneri.

Authors:  Elizabeth A Burton; Rina Plattner; Ann Marie Pendergast
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

9.  Development of a broad-spectrum antiviral with activity against Ebola virus.

Authors:  M Javad Aman; Michael S Kinch; Kelly Warfield; Travis Warren; Abdul Yunus; Sven Enterlein; Eric Stavale; Peifang Wang; Shaojing Chang; Qingsong Tang; Kevin Porter; Michael Goldblatt; Sina Bavari
Journal:  Antiviral Res       Date:  2009-06-10       Impact factor: 5.970

Review 10.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Authors:  E Weisberg; P Manley; J Mestan; S Cowan-Jacob; A Ray; J D Griffin
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

View more
  61 in total

Review 1.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

2.  Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.

Authors:  Szu-Yuan Pu; Randy Wouters; Stanford Schor; Jef Rozenski; Rina Barouch-Bentov; Laura I Prugar; Cecilia M O'Brien; Jennifer M Brannan; John M Dye; Piet Herdewijn; Steven De Jonghe; Shirit Einav
Journal:  J Med Chem       Date:  2018-07-16       Impact factor: 7.446

3.  Predictive and comparative analysis of Ebolavirus proteins.

Authors:  Qian Cong; Jimin Pei; Nick V Grishin
Journal:  Cell Cycle       Date:  2015-07-09       Impact factor: 4.534

4.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

5.  Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.

Authors:  Ziying Han; Jianhong Lu; Yuliang Liu; Benjamin Davis; Michael S Lee; Mark A Olson; Gordon Ruthel; Bruce D Freedman; Matthias J Schnell; Jay E Wrobel; Allen B Reitz; Ronald N Harty
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

6.  ITCH E3 Ubiquitin Ligase Interacts with Ebola Virus VP40 To Regulate Budding.

Authors:  Ziying Han; Cari A Sagum; Mark T Bedford; Sachdev S Sidhu; Marius Sudol; Ronald N Harty
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

7.  Synergistic drug combination effectively blocks Ebola virus infection.

Authors:  Wei Sun; Shihua He; Carles Martínez-Romero; Jennifer Kouznetsova; Gregory Tawa; Miao Xu; Paul Shinn; Ethan Fisher; Yan Long; Omid Motabar; Shu Yang; Philip E Sanderson; Peter R Williamson; Adolfo García-Sastre; Xiangguo Qiu; Wei Zheng
Journal:  Antiviral Res       Date:  2016-11-24       Impact factor: 5.970

8.  Could the Ebola virus matrix protein VP40 be a drug target?

Authors:  Robert V Stahelin
Journal:  Expert Opin Ther Targets       Date:  2013-11-28       Impact factor: 6.902

9.  Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.

Authors:  Christopher M Coleman; Jeanne M Sisk; Rebecca M Mingo; Elizabeth A Nelson; Judith M White; Matthew B Frieman
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes.

Authors:  Smita P Soni; Robert V Stahelin
Journal:  J Biol Chem       Date:  2014-10-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.